Liu et al., showed that PI3K plays a role as inducer of chemoresistance in CRC (Liu et al., 2017), and in CRC patients, PIK3CA mutation leads to the activation of PI3K/Akt signaling, and chemotherapy resistance (Wang et al., 2018a). Here, PIK3CA is linked to colorectal carcinoma.